Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Reagle

Pulmonary Disease Clarkston, MI Doctor of Osteopathy

NPI 1619959509 CMS profile 72830

5701 Bow Pointe Dr Ste 365, Clarkston, MI 48346

Open in the dashboard

General payments

$11,978

566 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Reagle of Clarkston, MI is reported in the CMS Open Payments database as having received $11,978 across 566 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26 1
2024 General $577 25
2023 General $2,822 108
2022 General $2,324 107
2021 General $2,373 117
2020 General $1,298 79
2019 General $2,557 129

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Reagle
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Robert Reagle were reported at $26. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Robert Reagle Pulmonary Disease median Middle half National median
2019 $2,557 $377 $109–$1,340 $163
2020 $1,298 $230 $56–$907 $114
2021 $2,373 $269 $68–$1,072 $132
2022 $2,324 $390 $100–$1,457 $149
2023 $2,822 $419 $114–$1,659 $160
2024 $577 $476 $123–$1,818 $164
2025 $26 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,207 100 payments
  2. GlaxoSmithKline, LLC. $1,794 90 payments
  3. Jazz Pharmaceuticals Inc. $1,545 50 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,187 52 payments
  5. Harmony Biosciences LLC $884 55 payments
  6. Mylan Specialty L.P. $516 23 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $433 21 payments
  8. Regeneron Healthcare Solutions, Inc. $425 17 payments
  9. Grifols USA, LLC $309 15 payments
  10. Alexion Pharmaceuticals, Inc. $255 12 payments
  11. Other $2,422 131 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,918 565 payments
  2. Education $60 1 payment
Products named General payments · program years 2019–2025
  1. XYWAV $966 25 payments
  2. BREZTRI $878 22 payments
  3. TRELEGY ELLIPTA $784 50 payments
  4. OFEV $647 29 payments
  5. STIOLTO RESPIMAT $592 25 payments
  6. SPIRIVA RESPIMAT $543 23 payments
  7. GLASSIA $503 25 payments
  8. Wakix $477 40 payments
  9. FASENRA $437 26 payments
  10. DUPIXENT $425 17 payments
  11. Other $7,135 351 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

527

Median for Pulmonary Disease: 936

Drug cost

$147,184

Median for Pulmonary Disease: $487,987

Branded share of claims

53.3%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 95 $99,670
Incruse Ellipta Umeclidinium Bromide Brand 21 $12,178
Symbicort Budesonide/Formoterol Fumarate Brand 27 $11,886
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 14 $9,990
Albuterol Sulfate Hfa Albuterol Sulfate Brand 94 $3,650
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 13 $3,574
Montelukast Sodium Generic 159 $2,623
Ventolin Hfa Albuterol Sulfate Brand 17 $2,460
Methylphenidate Hcl Generic 19 $404
Fluticasone Propionate Generic 25 $376

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$6,084

Medicare's payments for the services billed

Medicare patients

108

Average age 74

Services billed

145

47 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 52%
Ischemic heart disease 44%
Chronic kidney disease 31%
Atrial fibrillation 27%
COPD 27%
Cancer 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
  • Harmony Biosciences LLC $142
$142 — —
DUPIXENT
  • GENZYME CORPORATION $36
  • Regeneron Healthcare Solutions, Inc. $22
$57 — —
YUPELRI
  • Mylan Specialty L.P. $51
$51 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $38
$38 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

566 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record